Introduction: Who Should Undergo Diagnostics for Recurrent Multiple Myeloma

Anyone who has been treated for multiple myeloma needs ongoing monitoring throughout their life. The disease is chronic in nature, meaning that even when treatment works well and no signs of active myeloma remain—a state called remission—the cancer can return^[1]. This return of the disease is called a relapse, and it requires prompt evaluation and testing to determine the best path forward^[7].

You should seek diagnostic testing if you notice symptoms returning after a period of remission. Common warning signs include bone pain that reappears or worsens, new fatigue that interferes with daily activities, unusual weakness, frequent infections, or unexplained weight loss^[3]. Sometimes patients experience new symptoms they didn’t have during their initial diagnosis, such as mental confusion, increased thirst, or a need to urinate more often^[3].

Even if you feel well, regular scheduled check-ups with your healthcare team are essential. During the course of multiple myeloma, most patients will experience several cycles of remission and relapse^[7]. Your doctor will want to catch any signs of disease progression early, even before symptoms appear. This allows for timely intervention and can prevent complications such as kidney damage, severe bone destruction, or dangerously high calcium levels in the blood^[12].

People who have had myeloma in remission for longer periods may feel surprised when symptoms return. However, the risk of progression exists even years after successful treatment^[10]. The pattern of relapse varies from person to person. Some patients may stay in remission for many years, while others experience relapse more quickly after treatment ends^[9].

Diagnostic Methods for Identifying Recurrent Multiple Myeloma

When doctors suspect that multiple myeloma has returned, they use a combination of tests to confirm the diagnosis and understand how active the disease has become. These tests examine your blood, bone marrow, and urine, as well as imaging studies to look at your bones and organs^[1].

Blood Tests

Blood tests are fundamental to diagnosing recurrent myeloma. Your doctor will look for what is called M protein, which is an abnormal antibody produced by cancerous plasma cells^[1]. The amount of M protein in your blood helps indicate how active your myeloma is. A blood test called serum protein electrophoresis can measure this protein and track changes over time^[12].

Another important blood test measures free light chains. These are parts of antibodies that are produced in excess by myeloma cells. When these light chains become unbalanced, it suggests the disease is active^[12]. Your doctor will also check your complete blood count to see if you have anemia (low red blood cells), low white blood cells that fight infection, or reduced platelets that help blood clot^[3].

Blood tests also evaluate your kidney function and calcium levels. Multiple myeloma can damage the kidneys, and cancer cells can release calcium from damaged bones into the bloodstream, causing dangerous complications^[4]. These markers help doctors understand not just whether the disease has returned, but also whether it is causing organ damage that needs immediate attention.

Urine Tests

Urine testing complements blood work by detecting M protein that the kidneys filter out. A 24-hour urine collection allows doctors to measure the total amount of abnormal protein your body is producing^[1]. This test is particularly important because in some patients, myeloma cells produce proteins that show up more clearly in urine than in blood.

The urine test can also reveal whether myeloma is damaging your kidneys. When kidneys are injured by light chains or other proteins, they may leak other substances that shouldn’t normally appear in urine^[12]. Detecting kidney problems early allows for interventions to protect this vital organ.

Bone Marrow Examination

A bone marrow biopsy provides direct evidence of whether abnormal plasma cells have returned. During this procedure, a doctor removes a small sample of bone marrow, usually from the hip bone, using a special needle. The sample is then examined under a microscope to count the percentage of plasma cells and determine if they appear cancerous^[1].

For multiple myeloma to be diagnosed, more than 10 percent of the bone marrow must be made up of abnormal plasma cells, or there must be evidence of damage to bones or organs^[12]. The bone marrow biopsy can also reveal genetic changes in the cancer cells that might influence treatment decisions.

While a bone marrow biopsy might sound intimidating, it is usually done with local anesthesia to minimize discomfort. The information it provides is valuable because it directly shows what is happening inside your bones where myeloma cells grow^[2].

Imaging Studies

Imaging tests help doctors see whether myeloma has damaged your bones or formed tumors. X-rays can reveal areas where cancer has weakened bones, creating holes called osteolytic lesions^[4]. These weak spots increase the risk of fractures and can cause significant pain.

More advanced imaging may include CT scans, MRI scans, or PET scans. These provide detailed pictures of your skeleton and internal organs. A CT scan uses X-rays and computer processing to create cross-sectional images of your body. An MRI uses magnetic fields and radio waves to produce detailed images of soft tissues and bones. A PET scan can show areas where cancer cells are actively growing by detecting how they use sugar for energy^[12].

Imaging is particularly important when you have new bone pain or when other tests suggest the disease has progressed. It helps doctors locate exactly where the myeloma is causing problems so they can plan appropriate treatment, which might include targeted radiation for painful bone lesions^[1].

Understanding Test Results

Interpreting test results for recurrent myeloma involves looking at multiple pieces of information together. According to guidelines developed by the International Myeloma Working Group, relapsed refractory multiple myeloma means the disease has progressed or responded poorly despite treatment^[7]. Specifically, doctors look for at least a 25 percent increase in serum or urine M protein from its lowest point, or increases in free light chains^[7].

The results also help classify how the disease has relapsed. If your myeloma responds to treatment but then returns after more than 60 days, it’s called relapsed disease. If it progresses during treatment or within 60 days of your last therapy, it’s considered refractory^[7]. This distinction matters because it influences what treatments your doctor might recommend next.

Diagnostics for Clinical Trial Qualification

When standard treatments stop working or you’re exploring new options for recurrent myeloma, clinical trials may offer access to promising therapies. However, joining a clinical trial requires meeting specific eligibility criteria, which means undergoing additional diagnostic testing^[6].

Standard Diagnostic Criteria

Clinical trials for relapsed or refractory multiple myeloma typically require documentation that your disease has indeed progressed. This means your diagnostic tests must show evidence meeting the International Myeloma Working Group criteria for progression^[7]. Researchers need clear proof through blood tests, urine tests, and often bone marrow biopsies that show increasing myeloma activity.

Many trials also have requirements about your prior treatments. For example, some studies only accept patients who have received a certain number of previous therapies^[11]. You may need to provide detailed medical records documenting what treatments you received, how you responded, and when your disease relapsed. This helps researchers ensure they are testing new therapies in the right patient populations.

Performance Status and Organ Function Testing

Beyond confirming disease progression, clinical trials assess your overall health and ability to tolerate new treatments. Tests of your heart function, such as an electrocardiogram or echocardiogram, might be required to ensure the experimental therapy won’t be too risky for you. Similarly, lung function tests might be needed if the treatment could affect breathing^[9].

Kidney and liver function tests are almost always required. These organs process medications, and if they aren’t working well enough, you might not be able to safely receive certain treatments being studied^[12]. Your blood counts must also typically meet minimum thresholds, ensuring you have enough healthy blood cells to withstand the therapy being tested.

Specialized Testing for Targeted Therapies

Some clinical trials test treatments that work only against myeloma cells with specific characteristics. These trials may require what is called companion diagnostic testing, which looks for particular genetic markers or proteins on your cancer cells^[6]. For instance, researchers might need to confirm that your myeloma cells express a certain target protein that the new drug is designed to attack.

This specialized testing might involve examining your bone marrow sample or tumor tissue for specific genetic mutations or molecular features. Technologies like next-generation sequencing can identify these characteristics by analyzing the DNA of your cancer cells^[2]. While this adds complexity to the diagnostic process, it helps ensure that patients receive treatments most likely to work for their particular type of myeloma.

Baseline Measurements

Before starting any clinical trial treatment, researchers establish baseline measurements of your disease. This means repeating many of the standard diagnostic tests described earlier—blood tests, urine tests, bone marrow biopsies, and imaging studies^[12]. These baseline results serve as a starting point for comparison, allowing researchers to measure whether the experimental treatment is working.

Throughout the trial, you’ll undergo regular monitoring with the same tests to track your response to treatment. This frequent testing serves two purposes: it protects your safety by catching problems early, and it generates the data researchers need to determine whether the new therapy is effective. The schedule of these tests varies by trial but is typically more intensive than routine clinical care^[9].

Practical Considerations

Participating in a clinical trial often means more frequent visits to the clinic and more diagnostic procedures than standard care would require. While this can feel burdensome, many patients find value in the close monitoring and access to cutting-edge treatments. The trial team will explain exactly what tests are needed and why, and they should address any concerns you have about the procedures involved.

It’s worth noting that not everyone with recurrent myeloma will qualify for every trial. Eligibility criteria can be strict to ensure patient safety and generate reliable research data. If you don’t qualify for one trial, ask your healthcare team about other studies that might be a better fit for your situation^[6].